[Edaily JAEMIN SONG Choi Oh-hyun Reporter] “We are currently negotiating 2027 HBM prices with our customers, and the discussions are proceeding smoothly. HBM is a product that requires more wafers, advanced manufacturing processes, and significant production resources compared to standard DRAM. We determine prices by comprehensively considering not only standard DRAM prices but also the resources invested, opportunity costs, technical complexity, and the value the product provides to customers. We will maintain robust profitability based on our accumulated technology, cost competitiveness, stable mass production capabilities, and the trust and close cooperation of our customers.”
…SK hynix Q2 2026 Conference Call
A view of SK hynix’s headquarters in Icheon, Gyeonggi Province. (Photo: Yonhap News)
“Starting July 30—the day after Onejoon Co., Ltd.’s listing on the Korea Exchange is completed—ADRs can be freely converted into Onejoon Co., Ltd. shares. However, converting Onejoon Co., Ltd. shares …
Ingenia Therapeutics (Ingenia), an innovative antibody drug developer set to list on KOSDAQ, has brought a treatment for chronic kidney disease (CKD) to the negotiating table with a global big pharma …
AHNLAB,INC.(053800)announced preliminary financial results on the 29th, reporting consolidated revenue of 130.4 billion won and operating profit of 7.3 billion won for the first half of this year.
…
